Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems
Rhea-AI Summary
VolitionRx (NYSE AMERICAN: VNRX) has expanded its Nu.Q® Vet Cancer Test supply agreement with Fujifilm Vet Systems in Japan. The new five-year agreement includes Volition's chemiluminescent immunoassay (ChLIA) version via the IDS i10® automated analyzer platform.
The expansion builds upon the previous agreement that offered the manual ELISA format test. Fujifilm Vet Systems plans to launch the automated platform for canine cancer screening in summer 2025, following final validation and verification. Since the initial launch in July 2024, over 1,000 veterinary hospitals in Japan have registered to use the test.
The agreement allows Fujifilm Vet Systems to sell and perform the Nu.Q® Vet Cancer Test through its network of central reference laboratories in Japan, targeting a market of approximately seven million pet dogs.
Positive
- Over 1,000 veterinary hospitals in Japan already registered to use the test
- Access to market of 7 million pet dogs in Japan
- Automation upgrade will enable higher throughput and faster turnaround
- Five-year agreement extension with leading Japanese diagnostic provider
Negative
- Platform still requires final validation and verification before launch
News Market Reaction 1 Alert
On the day this news was published, VNRX gained 2.83%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Dr. Jasmine Kway, Chief Executive Officer of Singapore Volition added:
"There are approximately seven million pet dogs in
"We are delighted to have extended our agreement with Fujifilm Vet Systems to include our automated platform. This will greatly facilitate the increased demand with rapid turn around."
Kiyotaka Fujiwara, Chief Operating Officer at Fujifilm Vet Systems, said:
"Since our launch of the Nu.Q® Vet Cancer Test in July 2024, there has been an incredible amount of interest amongst Japanese veterinarians, indeed the number of veterinary hospitals registered to use the test in
Dr. Jasmine Kway, added:
"Cancer is the leading cause of adult canine deaths; earlier detection can improve outcomes. The Nu.Q® Vet Cancer Test is an accessible and affordable screening tool for dogs to aid in early cancer detection.
"This automated central lab platform is the same platform Volition utilizes for its human products, Nu.Q® Cancer, Nu.Q® NETs and Nu.Q® Discover demonstrating the synergy across the Nu.Q® technology platform."
Volition's supply agreement enables Fujifilm Vet Systems to sell and perform the Nu.Q® Vet Cancer Test throughout its network of central reference laboratories in
About the Nu.Q® Vet Cancer Test
The Nu.Q® Vet Cancer Test is intended for use during regular preventive check-ups of older dogs (seven years and older) or for younger dogs of high-risk breeds. At a global average price per test of
About FujiFilm Vet Systems
FujiFilm Vet Systems is a subsidiary of FujiFilm Holdings Corporation, listed on the
FujiFilm Vet Systems provides testing services centered on health checkups to veterinary medical facilities nationwide with relationships throughout the estimated 11,000 veterinary medical facilities in
About Volition
Volition is a multi-national epigenetics company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients, but also improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com, +44 (0)7557 774620
Investor Relations
Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com, +1-212-915-2568
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this press release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™, Capture-PCR™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
View original content:https://www.prnewswire.com/news-releases/volition-signs-first-ever-nuq-vet-cancer-test-automation-agreement-with-fujifilm-vet-systems-302401002.html
SOURCE VolitionRx Limited
FAQ
When will Volition's automated Nu.Q® Vet Cancer Test launch in Japan?
How many veterinary hospitals in Japan are using VNRX's Nu.Q® Vet Cancer Test?
What is the market size for VNRX's Nu.Q® Vet Cancer Test in Japan?
What improvements does the new automated Nu.Q® Vet Cancer Test offer?
How long is VNRX's new supply agreement with Fujifilm Vet Systems?
